Back to top

Image: Bigstock

Epizyme, Inc.

Read MoreHide Full Article

Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. However, the company suffered a setback when the FDA imposed a partial clinical hold on new enrollment of U.S. patients in the ongoing trials for tazemetostat. The company’s attention now is squarely focused on a set of actions intended to address the partial clinical hold.The company is assessing its timeline for submitting a new drug application to the FDA for tazemetostat regarding follicular lymphoma. The company plans to file a first new drug application for tazemetostat with respect to epithelioid sarcoma in the fourth quarter of 2018. A potential approval for the candidate will be a significant boost to the company.  Shares of the company have outperformed the industry in the year so far. However, the company is highly dependent on its collaboration partners for growth.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Epizyme, Inc. (EPZM) - free report >>

Published in